Avidity Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Avidity Biosciences (NASDAQ: RNA), a biopharmaceutical company focused on developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in three upcoming investor conferences in September 2025.
The management team will participate in fireside chats at the Cantor Global Healthcare Conference on September 3, the Wells Fargo Healthcare Conference on September 4, and the Morgan Stanley Global Healthcare Conference on September 8. Live webcasts and replays will be available on the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RNA gained 1.64%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Cantor Global Healthcare Conference 2025 –
New York, NY
Wednesday, September 3, 2025, at 7:20 a.m. PT | 10:20 a.m. ET - 2025 Wells Fargo Healthcare Conference –
Everett, MA
Thursday, September 4, 2025, at 9:45 a.m. PT | 12:45 p.m. ET - Morgan Stanley 23rd Annual Global Healthcare Conference –
New York, NY
Monday, September 8, 2025, at 10:50 a.m. PT | 1:50 p.m. ET
Live webcasts of each event, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in
Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-302538395.html
SOURCE Avidity Biosciences, Inc.
FAQ
When is Avidity Biosciences (RNA) presenting at the Cantor Global Healthcare Conference 2025?
What type of events will Avidity Biosciences (RNA) participate in at these healthcare conferences?
Where can investors watch Avidity Biosciences' (RNA) conference presentations?
What is Avidity Biosciences' (RNA) main focus as a company?
